

# Global Veterinary Renal Disease Market Size study, by Type, by Animal Type (Canine, Feline, Bovine, Equine, Others), by Route of Administration, by Indication, by Distribution Channel and Regional Forecasts 2022-2032

<https://marketpublishers.com/r/G46305E79601EN.html>

Date: May 2025

Pages: 285

Price: US\$ 3,750.00 (Single User License)

ID: G46305E79601EN

## Abstracts

Global Veterinary Renal Disease Market is valued at approximately USD 25.33 billion in 2023 and is anticipated to grow with a steady compound annual growth rate of more than 5.49% over the forecast period 2024-2032. Veterinary renal disease, affecting a significant portion of the global companion and livestock animal population, is rapidly gaining attention within the broader animal health domain. This progressive condition, especially prevalent in geriatric canines and felines, manifests through chronic kidney damage that impairs filtration, electrolyte balance, and systemic homeostasis. In commercial settings such as dairy and breeding farms, renal dysfunction in animals like bovines and equines can compromise productivity and lead to substantial economic setbacks. Consequently, stakeholders are turning to advanced diagnostics, disease-modifying drugs, and supportive treatments designed to manage the multifactorial nature of renal disorders in animals.

The growing recognition of chronic kidney disease (CKD) as a leading cause of morbidity among pets, coupled with increasing veterinary visits and awareness campaigns, is pushing both pet owners and livestock managers to seek timely interventions. The veterinary renal disease market is also benefitting from the convergence of technological innovations in diagnostic imaging, biosensing, and personalized drug formulations. In particular, the introduction of therapeutic diets, phosphate binders, angiotensin-converting enzyme (ACE) inhibitors, and advanced intravenous solutions is redefining treatment protocols. However, limitations around early diagnosis, especially in asymptomatic stages, and the high cost burden of

continuous therapy in rural or underfunded veterinary setups remain core challenges.

A surge in veterinary health insurance coverage, alongside increased pet ownership in urban settings, is influencing treatment accessibility and driving market penetration of premium therapeutic regimens. Additionally, the focus on minimally invasive delivery methods, such as oral rehydration solutions and transdermal medications, is reshaping patient compliance and treatment adherence. With companies developing species-specific formulations and route-optimized drug delivery systems, new avenues are opening for effective renal disease management. Furthermore, the adoption of artificial intelligence (AI) and machine learning for predictive diagnostics and prognosis evaluation is expected to enhance clinical decision-making over the forecast period.

Geographically, North America represents the most mature and dominant market for veterinary renal disease solutions, attributed to a high density of veterinary clinics, specialist care infrastructure, and leading pharmaceutical innovation. Europe trails closely, supported by regulatory support for animal welfare and robust funding for animal health research. The Asia Pacific region is forecasted to register the fastest growth, bolstered by rising disposable incomes, booming companion animal populations, and supportive government policies for livestock healthcare in emerging economies like India, China, and Southeast Asia. Latin America and the Middle East & Africa, while in earlier stages of development, are progressively witnessing adoption driven by increasing awareness and infrastructure investments.

Major market player included in this report are:

Elanco Animal Health Incorporated

Virbac

Boehringer Ingelheim International GmbH

Zoetis Inc.

Vetoquinol S.A.

Dechra Pharmaceuticals PLC

Merck & Co., Inc.

Ceva Sante Animale

IDEXX Laboratories, Inc.

Norbrook

Hill's Pet Nutrition Inc.

Medtronic Plc

Bayer AG

Karyopharm Therapeutics Inc.

B. Braun Vet Care GmbH

The detailed segments and sub-segment of the market are explained below:

#### By Type

Acute Renal Disease

Chronic Renal Disease

#### By Animal Type

Canine

Feline

Bovine

Equine

Others

## By Route of Administration

Oral

Injectable

Others

## By Indication

Dehydration

Hypertension

Electrolyte Imbalance

Proteinuria

Others

## By Distribution Channel

Veterinary Hospitals

Retail Pharmacies

Online Pharmacies

Others

## By Region:

North America

U.S.

Canada

## Europe

UK

Germany

France

Spain

Italy

ROE

## Asia Pacific

China

India

Japan

Australia

South Korea

RoAPAC

## Latin America

Brazil

Mexico

Middle East & Africa

Saudi Arabia

South Africa

RoMEA

Years considered for the study are as follows:

Historical year – 2022

Base year – 2023

Forecast period – 2024 to 2032

Key Takeaways:

Market Estimates & Forecast for 10 years from 2022 to 2032.

Annualized revenues and regional level analysis for each market segment.

Detailed analysis of geographical landscape with country level analysis of major regions.

Competitive landscape with information on major players in the market.

Analysis of key business strategies and recommendations on future market approach.

Analysis of competitive structure of the market.

Demand side and supply side analysis of the market.

## Contents

### **CHAPTER 1. GLOBAL VETERINARY RENAL DISEASE MARKET EXECUTIVE SUMMARY**

- 1.1. Global Veterinary Renal Disease Market Size & Forecast (2022–2032)
- 1.2. Regional Summary
- 1.3. Segmental Summary
  - 1.3.1. By Type (Acute Renal Disease; Chronic Renal Disease)
  - 1.3.2. By Animal Type (Canine; Feline; Bovine; Equine; Others)
  - 1.3.3. By Route of Administration (Oral; Injectable; Others)
  - 1.3.4. By Indication (Dehydration; Hypertension; Electrolyte Imbalance; Proteinuria; Others)
  - 1.3.5. By Distribution Channel (Veterinary Hospitals; Retail Pharmacies; Online Pharmacies; Others)
- 1.4. Key Trends
- 1.5. Recession Impact
- 1.6. Analyst Recommendation & Conclusion

### **CHAPTER 2. GLOBAL VETERINARY RENAL DISEASE MARKET DEFINITION AND RESEARCH ASSUMPTIONS**

- 2.1. Research Objective
- 2.2. Market Definition
- 2.3. Research Assumptions
  - 2.3.1. Inclusion & Exclusion
  - 2.3.2. Limitations
  - 2.3.3. Supply Side Analysis
    - 2.3.3.1. Availability
    - 2.3.3.2. Infrastructure
    - 2.3.3.3. Regulatory Environment
    - 2.3.3.4. Market Competition
    - 2.3.3.5. Economic Viability (Consumer's Perspective)
  - 2.3.4. Demand Side Analysis
    - 2.3.4.1. Regulatory Frameworks
    - 2.3.4.2. Technological Advancements
    - 2.3.4.3. Environmental Considerations
    - 2.3.4.4. Consumer Awareness & Acceptance
- 2.4. Estimation Methodology

- 2.5.?Years Considered for the Study
- 2.6.?Currency Conversion Rates

## **CHAPTER 3.?GLOBAL VETERINARY RENAL DISEASE MARKET DYNAMICS**

- 3.1.?Market Drivers
  - 3.1.1.?Rising Prevalence of Chronic Kidney Disease in Companion Animals
  - 3.1.2.?Technological Innovations in Diagnostics and Therapeutics
  - 3.1.3.?Expansion of Veterinary Health Insurance Coverage
- 3.2.?Market Challenges
  - 3.2.1.?High Cost and Limited Access to Early Diagnostic Tools
  - 3.2.2.?Lack of Awareness in Rural and Underfunded Veterinary Settings
- 3.3.?Market Opportunities
  - 3.3.1.?AI?Driven Predictive Diagnostics and Prognosis Evaluation
  - 3.3.2.?Development of Species Specific Formulations and Drug Delivery Systems
  - 3.3.3.?Growth in Minimally Invasive and Transdermal Therapies

## **CHAPTER 4.?GLOBAL VETERINARY RENAL DISEASE MARKET INDUSTRY ANALYSIS**

- 4.1.?Porter's Five Forces Model
  - 4.1.1.?Bargaining Power of Suppliers
  - 4.1.2.?Bargaining Power of Buyers
  - 4.1.3.?Threat of New Entrants
  - 4.1.4.?Threat of Substitutes
  - 4.1.5.?Competitive Rivalry
  - 4.1.6.?Futuristic Approach to Porter's Five Forces
  - 4.1.7.?Porter's Five Forces Impact Analysis
- 4.2.?PESTEL Analysis
  - 4.2.1.?Political
  - 4.2.2.?Economic
  - 4.2.3.?Social
  - 4.2.4.?Technological
  - 4.2.5.?Environmental
  - 4.2.6.?Legal
- 4.3.?Top Investment Opportunity
- 4.4.?Top Winning Strategies
- 4.5.?Disruptive Trends
- 4.6.?Industry Expert Perspective

4.7. Analyst Recommendation & Conclusion

## **CHAPTER 5. GLOBAL VETERINARY RENAL DISEASE MARKET SIZE & FORECASTS BY TYPE 2022–2032**

5.1. Segment Dashboard

5.2. Global Veterinary Renal Disease Market: Type Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)

5.2.1. Acute Renal Disease

5.2.2. Chronic Renal Disease

## **CHAPTER 6. GLOBAL VETERINARY RENAL DISEASE MARKET SIZE & FORECASTS BY ANIMAL TYPE 2022–2032**

6.1. Segment Dashboard

6.2. Global Veterinary Renal Disease Market: Animal Type Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)

6.2.1. Canine

6.2.2. Feline

6.2.3. Bovine

6.2.4. Equine

6.2.5. Others

## **CHAPTER 7. GLOBAL VETERINARY RENAL DISEASE MARKET SIZE & FORECASTS BY REGION 2022–2032**

7.1. North America Market

7.1.1. U.S. Market

7.1.1.1. By Type Breakdown, 2022–2032

7.1.1.2. By Animal Type Breakdown, 2022–2032

7.1.2. Canada Market

7.2. Europe Market

7.2.1. U.K. Market

7.2.2. Germany Market

7.2.3. France Market

7.2.4. Spain Market

7.2.5. Italy Market

7.2.6. Rest of Europe Market

7.3. Asia Pacific Market

- 7.3.1. China Market
- 7.3.2. India Market
- 7.3.3. Japan Market
- 7.3.4. Australia Market
- 7.3.5. South Korea Market
- 7.3.6. Rest of Asia Pacific Market
- 7.4. Latin America Market
  - 7.4.1. Brazil Market
  - 7.4.2. Mexico Market
- 7.5. Middle East & Africa Market
  - 7.5.1. Saudi Arabia Market
  - 7.5.2. South Africa Market
  - 7.5.3. Rest of Middle East & Africa Market

## **CHAPTER 8. COMPETITIVE INTELLIGENCE**

- 8.1. Key Company SWOT Analysis
  - 8.1.1. Elanco Animal Health Incorporated
  - 8.1.2. Virbac
  - 8.1.3. Boehringer Ingelheim International GmbH
- 8.2. Top Market Strategies
- 8.3. Company Profiles
  - 8.3.1. Elanco Animal Health Incorporated
    - 8.3.1.1. Key Information
    - 8.3.1.2. Overview
    - 8.3.1.3. Financial (Subject to Data Availability)
    - 8.3.1.4. Product Summary
    - 8.3.1.5. Market Strategies
  - 8.3.2. Virbac
  - 8.3.3. Boehringer Ingelheim International GmbH
  - 8.3.4. Zoetis Inc.
  - 8.3.5. Vetoquinol S.A.
  - 8.3.6. Dechra Pharmaceuticals PLC
  - 8.3.7. Merck & Co., Inc.
  - 8.3.8. Ceva Sante Animale
  - 8.3.9. IDEXX Laboratories, Inc.
  - 8.3.10. Norbrook
  - 8.3.11. Hill's Pet Nutrition Inc.
  - 8.3.12. Medtronic Plc

8.3.13. Bayer AG

8.3.14. Karyopharm Therapeutics Inc.

8.3.15. Braun Vet Care GmbH

## **CHAPTER 9. RESEARCH PROCESS**

9.1. Research Process

9.1.1. Data Mining

9.1.2. Analysis

9.1.3. Market Estimation

9.1.4. Validation

9.1.5. Publishing

9.2. Research Attributes

## I would like to order

Product name: Global Veterinary Renal Disease Market Size study, by Type, by Animal Type (Canine, Feline, Bovine, Equine, Others), by Route of Administration, by Indication, by Distribution Channel and Regional Forecasts 2022-2032

Product link: <https://marketpublishers.com/r/G46305E79601EN.html>

Price: US\$ 3,750.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G46305E79601EN.html>